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bjectives The RESOLUTE trial examined the safety and efﬁcacy of a next-generation zotarolimus-
luting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California).
ackground Revascularization beneﬁts associated with current drug-eluting stents are often dimin-
shed in the presence of complex coronary lesions and in certain patient cohorts. Resolute uses a
ew proprietary polymer coating that extends the duration of drug delivery to match the longer
ealing duration often experienced in more complex cases.
ethods The RESOLUTE trial was a prospective, nonrandomized, multicenter study of the Resolute
tent in 139 patients with de novo coronary lesions with reference vessel diameters 2.5 and 3.5
m and lesion length 14 and 27 mm. The primary end point was 9-month in-stent late lumen
oss by quantitative coronary angiography. Secondary end points included major adverse cardiac
vents (MACE) at 30 days, 6, 9, and 12 months; acute device, lesion, and procedure success; and
-month target vessel failure (TVF), target lesion revascularization (TLR), stent thrombosis, neointimal
yperplastic (NIH) volume, and percent NIH volume obstruction.
esults The 9-month in-stent late lumen loss was 0.22  0.27 mm. Cumulative MACE were 4.3%,
.3%, 7.2%, and 8.7% at 30 days, 6, 9, and 12 months, respectively. Acute lesion, procedure, and de-
ice success rates were 100.0%, 95.7%, and 99.3%, respectively. At 9 months, TLR was 0.0%, TVF was
.5%, stent thrombosis was 0.0%, NIH volume was 6.55  7.83 mm3, and percent NIH volume ob-
truction was 3.73  4.05%.
onclusions In this feasibility study, the Resolute stent demonstrated low in-stent late lumen loss,
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978rug-eluting stents (DES) have significantly reduced the
ates of clinical and angiographic restenosis compared with
are-metal stents (BMS) in patients undergoing percutane-
us coronary interventions for symptomatic coronary artery
isease (1–3). However, the revascularization benefits with
ES are often diminished in the presence of high-risk
esions and in certain patient cohorts, such as patients with
iabetes (4), patients with diffuse or multivessel disease,
atients with chronic renal failure (5), patients with left
ain disease or ostial disease, or patients who present with
hronic total occlusions (6).
See page 986
The Resolute (Medtronic Car-
dioVascular, Inc., Santa Rosa,
California) is a next-generation
zotarolimus-eluting stent (ZES)
system designed to match the ef-
ficacy and safety of the Endeavor
stent (Medtronic) while improv-
ing clinical outcomes in more
complex lesion subsets. The Res-
olute stent consists of the antipro-
liferative agent zotarolimus and
the low-profile, thin-strut Driver
(Medtronic) BMS platform, like
the Endeavor stent. However, in-
stead of the phosphorylcholine
coating of the Endeavor stent, the
Resolute stent employs the Bi-
oLinx tri-polymer coating to ex-
tend drug elution to match the
potentially delayed arterial healing
times associated with treatment of
more complex lesions and to com-
bat the greater sustained stimulus
to the proliferative response in
these more difficult patients (7).
The objectives of this first-in-
uman, prospective, nonrandomized, multicenter study of the
esolute stent system were to: 1) assess the early feasibility and
afety of implanting the Resolute stent system in human
oronary arteries on the basis of acute success rates and
ncidence of major adverse cardiac events (MACE) at 30 days;
nd 2) assess the medium-term safety and efficacy of the
esolute stent system on the basis of in-segment late lumen
oss at 9 months and the cumulative incidence of MACE at 6,
, and 12 months.
ethods
tudy overview and patient population. The RESOLUTE
bbreviations
nd Acronyms
RC  Academic Research
onsortium
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
VUS  intravascular
ltrasound
IA  late incomplete
pposition
ACE  major adverse
ardiac events
I  myocardial infarction
LD  minimal lumen
iameter
IH  neointimal hyperplasia
CA  quantitative coronary
ngiography
LR  target lesion
evascularization
VF  target vessel failure
VR  target vessel
evascularization
ES  zotarolimus-eluting
tent(s)rial was a prospective, multicenter, nonrandomized, single- arm study of the use of the Resolute stent to treat 139
onsecutive patients with symptomatic ischemic heart dis-
ase attributable to native coronary artery stenosis amenable
o treatment by percutaneous stenting. Of the 139 consec-
tive patients enrolled, the first 30 consented to a 4-month
ollow-up evaluation by quantitative coronary angiography
QCA) and intravascular ultrasound (IVUS) measurements,
nd the next 100 consented to a 9-month follow-up
valuation by QCA and IVUS. Nine additional patients
ere enrolled as part of a pharmacokinetic substudy and
ere not required to undergo baseline IVUS or 4-month or
-month angiographic and IVUS evaluation (Fig. 1). The
esults of the 4-month, 30-patient cohort were reported
reviously (8).
The study was conducted according to the Declaration of
elsinki, and local ethics committees approved the study
rotocol. All patients provided signed, written consent.
ndividuals eligible for enrollment were consecutive patients
8 years of age or older with symptomatic ischemic heart
isease due to de novo stenotic lesions (50% angiographic
iameter stenosis by visual estimate) in native coronary
rteries. The target lesion had to be a single de novo lesion
n a native coronary artery with a reference vessel diameter
2.5 and3.5 mm, a lesion length14 and27 mm, and
Thrombolysis In Myocardial Infarction flow grade 2.
atients were excluded if they experienced a recent (72 h)
yocardial infarction (MI), underwent prior stent place-
ent within the target vessel or any other vessel within 30
ays before the index procedure, or had any general contra-
ndication to the revascularization procedure and routine
ual antiplatelet therapies. Principal angiographic exclusion
riteria were: left main or ostial target lesion; severe calci-
cation by angiography; bifurcation lesion; location of the
arget lesion at a 45° bend; significant stenosis 50%
roximal or distal to the target lesion that might require
evascularization or impede runoff; involvement of a side
ranch 2.0 mm in diameter; or left ventricular ejection
raction 30%.
evice description. The Resolute stent is similar to the
ndeavor stent except that the biomimetic phosphorylcholine
rug carrier of the Endeavor stent is replaced with the BioLinx
olymer system. The BioLinx polymer system (7) consists of a
lend of 3 different polymers: 1) the hydrophobic C10 poly-
er, which aids in the control of drug release; 2) the hydro-
hilic C19 polymer, which supports biocompatibility; and
) polyvinyl pyrrolidinone, which increases the initial drug
urst and enhances the elution rate (9). Like the phosphoryl-
holine coating of the Endeavor stent, the new polymer
oating of the Resolute is biocompatible. The hydrophilic
urface mimics the body’s biological chemistry, thereby reduc-
ng the risk of an inflammatory response.
Autopsy examinations have identified polymer hypersensitivity
s 1 possible risk factor contributing to stent-thrombosis deaths
ssociated with first-generation sirolimus- and paclitaxel-eluting
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979tents (10,11). In a study comparing the Resolute stent,
ncluding the new polymer coating, with the Driver BMS in
orcine coronary arteries, there were no significant inflam-
atory differences between the cohorts at 28 days, and
ndothelialization in the presence of the BioLinx polymer
as rapid and complete (12). In another study comparing
he Endeavor stent and the Resolute stent in porcine
oronary arteries, biocompatibility was similar out to 180
ays (12).
The BioLinx coating of the Resolute stent enables finer
ontrol of the rate of drug elution. Although the zotaroli-
us dose is similar for the Endeavor stent and the Resolute
tent, drug elution is slower with the Resolute stent,
esulting in an extended duration of drug availability to the
Figure 1. Patient Disposition
Of the 139 consecutive patients enrolled in the RESOLUTE trial, the ﬁrst 30
(QCA) and intravascular ultrasound (IVUS), and the next 100 consented to a
as part of a pharmacokinetic (PK) substudy and were not required to undergo
patients completed 12-month clinical follow-up. *3 patients died, and 1 was lorterial tissue. In the porcine model, the Resolute stent wlutes 85% of its zotarolimus content during the first 60 days
fter procedure, and the remainder of the drug is completely
luted by 180 days (Fig. 2) (12).
nterventional procedure and adjunctive drug therapies.
welve sites in Australia and New Zealand participated in
his study. Stents were deployed according to standard
rocedure. Heparin was administered to maintain an acti-
ated clotting time 250 s or between 200 and 250 s if a
lycoprotein IIb/IIIa receptor inhibitor was administered.
atients received aspirin (at least 75 mg daily, within 24 h
efore the procedure and continued indefinitely after the
rocedure) and clopidogrel (300-mg loading dose within
4 h before the procedure and then 75 mg daily for a
inimum of 6 months after the procedure). Pre-dilation
nted to a 4-month follow-up with quantitative coronary angiography
nth follow-up with QCA and IVUS. Nine additional patients were enrolled
ine IVUS or 4- or 9-month angiographic and IVUS evaluation. A total of 135
ollow-up.conse
9-mo
baselas mandatory and undertaken with a balloon length
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980horter than the stent. Post-dilation, if required, was also
erformed with a balloon length less than or equal that of
he stent. Resolute stents were available in diameters rang-
ng from 2.5 to 3.5 mm and in lengths from 8 to 30 mm.
ata management and core laboratories. Conduct of the
rial was monitored by a contract research organization
Pacific Clinical Research Group, New South Wales, Aus-
ralia). All data were submitted to a central data coordinat-
ng facility (Cardiovascular Data Analysis Center, Harvard
linical Research Institute, Boston, Massachusetts). All
vents were adjudicated by an independent clinical events
ommittee managed by the Harvard Clinical Research
nstitute.
Coronary angiograms performed at baseline and at 4- and
-month follow-up were reviewed by an independent an-
iographic core laboratory (Brigham and Women’s Angio-
raphic Core Laboratory, Boston, Massachusetts). Standard
mage acquisition was performed with 2 or more angio-
raphic projections of the stenosis before and after stent
lacement. Qualitative analysis was performed on the basis of
he modified American College of Cardiology/American
eart Association classification (13). Quantitative angio-
raphic analysis was performed on the basis of a validated
utomated edge detection algorithm (Medis CMS, Leiden,
he Netherlands) (14). Frames were selected for analysis in
he 2 “sharpest and tightest” views that minimized fore-
hortening and vessel overlap. The contrast-filled injection
atheter was used as the calibration source. The IVUS
mages were also examined by an independent core labora-
ory (Cardiovascular Core Analysis Laboratory, Stanford
niversity, Palo Alto, California) (15,16). For both coro-
ary angiograms and IVUS images, quantitative analysis
Figure 2. The In Vivo Elution of the Resolute Zotarolimus-Eluting Stent Sys
The Resolute stent elutes 85% of zotarolimus during the ﬁrst 60 days after p
Reprinted with permission from Meredith et al. (8). LOQ  level of quantiﬁcatias performed to evaluate the in-stent region (bordered by she stent margins) as well as the in-segment region (in-stent
egion plus 5-mm margins proximal and distal to the stent).
tudy end points and deﬁnitions. The primary efficacy end
oint, in-stent late lumen loss, was examined by QCA at the
-month follow-up. Secondary angiographic and IVUS
fficacy end points included in-segment late lumen loss at 9
onths, angiographic binary restenosis (both in-stent and
n-segment) at 9 months, and percent volume obstruction
ssessed by IVUS at 9 months. A tertiary analysis was also
erformed comparing the 9-month in-stent late lumen loss
n the RESOLUTE trial with the historical ENDEAVOR
I trial matched patient subset (patients who received the
ndeavor ZES).
Late lumen loss was defined as the difference between the
inimal lumen diameter (MLD) at the completion of the
tenting procedure and the MLD measured at angiographic
ollow-up. Angiographic binary restenosis was defined as a
tenosis 50% of the lumen diameter of the target lesion
determined by the angiographic core laboratory). Reference
essel diameter was defined as the average of the normal
egments within 10 mm proximal and distal to the target
esion from 2 orthogonal views with QCA. Percent diam-
ter stenosis was defined as: (1  [MLD/reference vessel
iameter]  100), and acute gain was defined as the MLD
mmediately after the procedure minus the MLD before the
rocedure. Neointimal hyperplastic (NIH) area was com-
uted as stent minus lumen area. Volumetric analysis was
erformed by means of Simpson’s method for the entire
tented segment. In detailed analysis, NIH growth was
nalyzed as NIH area/volume divided by the corresponding
tent area/volume to adjust for the different stent sizes. The
ntire in-stent NIH growth was evaluated as percent NIH
olume (i.e., NIH volume  100/stent volume). The most
ure, and the remainder of the drug is completely eluted at 180 days.tem
rocedevere luminal obstruction by NIH growth within the stent
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981egment was determined as the maximum of percent NIH
rea (i.e., NIH area  100/stent area).
Secondary clinical safety and efficacy end points included
ACE (defined as the composite of all-cause death, MI,
nd clinically driven target lesion revascularization [TLR]);
he individual components of the composite end point
n-hospital, at 30 days and at 6, 9, and 12 months; stent
hrombosis (acute, 1 day; subacute, 1 to 30 days; and late,
30 days); clinically driven target vessel revascularization
TVR) at 9 months; and target vessel failure (TVF) (com-
osite of cardiovascular death, MI, and clinically driven
VR) at 9 months.
Death was defined as the occurrence of death from any
ause during the study period. Myocardial infarction was
efined as a creatine kinase elevation 2 times above the
pper limit of normal with any associated elevation in the
yocardial band or the development of new pathologic Q
aves in 2 contiguous electrocardiographic leads. Target
esion revascularization was defined as any percutaneous
ntervention or bypass surgery performed on the index target
esion at any time after the index procedure. Target vessel
evascularization was defined as any percutaneous interven-
ion or bypass surgery performed on the index target vessel
t any time after the index procedure. Stent thrombosis was
efined as an acute coronary syndrome with angiographic
ocumentation of vessel occlusion or thrombus within or
djacent to a previously stented segment, consistent with the
NDEAVOR I to IV clinical studies (17–21); in the
bsence of angiography, stent thrombosis could be con-
rmed by acute MI in the distribution of the treated vessel
r death resulting from cardiac causes within 30 days. All
tent thrombosis events were also adjudicated according to
cademic Research Consortium (ARC) criteria (22).
Acute lesion success was defined as achievement of a target
esion percent diameter stenosis 50% by any method; device
uccess was defined as acute lesion success with only the
esolute stent; and procedure success was defined as device
uccess without in-hospital MACE.
tatistical methods. The main objective of the RESOLUTE
rial was to demonstrate the acute safety of the Resolute ZES
nd gather information on the mid- and long-term safety
nd efficacy of the device. Therefore the trial was designed
o minimize the number of subjects exposed to the device
hile still providing enough information on safety and
fficacy. A sample size of 139 subjects was deemed sufficient
o provide reasonable confidence in the estimates of safety
nd efficacy generated by this study. All analyses were made
n an intention-to-treat basis, defined as the set of 139
atients with qualifying stenosis in which treatment with
he Resolute stent system was intended (i.e., all patients in
hom a guidewire was used to initiate the procedure).
ngiographic and IVUS data, collected at baseline and at 4-
r 9-month follow-up, were analyzed on all RESOLUTE
atients with technically successful paired data for the pairwiseomparisons. Categorical variables were tested with contin-
ency tables analyses (exact or chi-square approximations), and
ontinuous variables were tested with unpaired Student t test or
ilcoxon rank sum test, depending on variable distribution.
omparisons between matched cohorts of the RESOLUTE
nd ENDEAVOR II studies were presented with differences
with 95% confidence intervals) and p values. All statistical
ests were 2-sided, and a p value 0.05 was considered
tatistically significant.
esults
atient characteristics. Baseline clinical characteristics for
ll 139 patients are reported in Table 1. The age, sex-
istribution, and risk-factor profiles of the study patients
ere consistent with those of a population of patients
resenting with ischemic symptoms due to a discrete de
ovo lesion in a single native coronary artery (23).
rocedural outcomes. Procedural and lesion characteristics
re summarized in Table 2. Of the 139 patients enrolled,
here were 140 lesions (in 1 patient, the treated lesion was
ater adjudicated by the angiographic core laboratory as
eing 2 lesions in the same vessel.). The mean lesion length
as 15.61  6.13 mm. The acute lesion success rate was
00.0% (140 of 140), the procedure success rate was 95.7%
133 of 139), and the device success rate was 99.3% (139 of
40).
ngiographic and IVUS outcomes. The 4- and 9-month
CA results are presented in Table 3. At 4 months, the
n-stent late lumen loss was 0.12  0.26 mm, the
n-segment late lumen loss was 0.05  0.20 mm, and
oth the in-stent and -segment binary angiographic
estenosis were 0.0%.
At 9 months, the in-stent late lumen loss was 0.22 0.27
m, and in-segment late lumen loss was 0.12  0.27 mm.
here were no significant edge effects. At 9 months,
n-stent binary restenosis was 1.0%, and in-segment binary
estenosis was 2.1%. Compared with the matched cohort
rom the ENDEAVOR II study (18), the 9-month in-stent
ate lumen loss with the Resolute stent was significantly less
han that seen with the Endeavor stent (0.62  0.46 mm)
difference  0.39 mm [95% confidence interval: 0.49
o 0.29], p  0.001).
Table 1. Patient Characteristics (n  139)
Age (yrs) 60.7 10.0
Male 76.3
Diabetes mellitus 17.3
Hyperlipidemia 94.2
History of smoking 70.5
Prior myocardial infarction 46.4
Prior percutaneous coronary intervention 18.7Values are mean SD or %.
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982The 4- and 9-month IVUS results are presented in
able 4. The mean external elastic membrane volume after
rocedure at 4 and 9 months were similar, indicating that
here was no significant positive or negative remodeling
verall. Moreover, the stent volume was similar, indicating
o stent recoil. The NIH volume was 0.55  1.38 mm3
fter procedure, 3.72  4.21 mm3 at 4 months, and 6.55 
.83 mm3 at 9 months. The percent NIH volume obstruc-
ion was 2.23  2.43% at 4 months and 3.73  4.05% at 9
onths. Six late incomplete appositions (LIA) (involving 1
r more stent struts) were identified, with 2 involving the
dge of the stent and 4 involving the body of the stent. One
IA was associated with positive vessel remodeling (external
lastic membrane volume: after procedure  231.7 mm3; at
ollow-up  258.9 mm3; percent difference  11.7%),
hereas the other 5 were modest.
linical outcomes. Table 5 summarizes the cumulative com-
osite and component MACE at 30 days, 6, 9, and 12
onths. Figure 3 presents the cumulative incidence of TLR
nd cardiac death and MI through 12 months and dual
ntiplatelet therapy at 30 days, 6, 9, and 12 months. The
0-day incidence of MACE was 4.3%, which consisted
ntirely of 6 cases of periprocedural non–Q-wave MI. Of
hese 6 events, 5 occurred at the time of the index procedure
Table 2. Procedural and Lesion Characteristics
Characteristic
139 Patients
140 Lesions
Target artery
Left anterior descending 34.3
Left circumﬂex 25.7
Right coronary artery 40.0
ACC/AHA class
A 1.4
B1 17.1
B2 49.3
C 32.1
Length of lesion (mm) 15.61 6.13
Pre-procedure reference vessel diameter (mm) 2.81 0.40
Minimal lumen diameter (mm) 0.83 0.34
Acute gain (mm) [in-stent] 1.93 0.45
Acute gain (mm) [in-segment] 1.53 0.51
Diameter stenosis [pre] 70.30 11.37
Diameter stenosis [post] 3.36 8.54
Device- success* 99.3
Procedure success† 95.7
Lesion success‡ 100.0
Values are % or mean  SD. *Device success was defined as 50% residual in-segment final
stenosis with only the Resolute stent. †Procedure success was defined as 50% residual in-
segment final stenosis with the Resolute stent without amajor adverse cardiac event in-hospital.
‡Lesion success was defined as50% residual in-segment final stenosis.
ACC American College of Cardiology; AHA American Heart Association.nd were due to factors that occurred before study stentmplantation. All 6 cases of periprocedural non–Q-wave MI
esolved uneventfully.
From 30 days to 9 months, 4 additional events
ccurred—1 cardiac death, 1 noncardiac death, and 2
atrogenic non–Q wave MIs precipitated by protocol man-
ated follow-up—resulting in a 9-month cumulative
ACE of 7.2% (10 of 139).
From 9 months to 12 months there was 1 additional
oncardiac death due to cancer and 1 TLR, resulting in
12-month cumulative incidence of MACE of 8.7% (12
f 138). The cumulative incidence of TVF at 9 months
as 6.5%; at 12 months it was 7.2%. According to
rotocol-specified definitions, there were no cases of
tent thrombosis through 12 months; however, there was
case of possible stent thrombosis with ARC criteria
22).
iscussion
n this first-in-human feasibility study, RESOLUTE, we
eport the safety and efficacy of the Resolute stent, which
onsists of the low-profile, thin-strut Driver BMS platform,
he antiproliferative agent zotarolimus, and the new propri-
tary biomimetic BioLinx polymer system. Overall, the
esolute stent demonstrated a safety profile comparable to
hat of the Endeavor stent (17–20). In the RESOLUTE
rial, patient, vessel, and lesion characteristics were similar to
revious first-in-human DES studies (17,24–27), although
he average lesion length was longer (15.61 6.13 mm) and
here were more B2/C lesions (81%) in the present study.
espite the longer lesion length and complexity, the Res-
Table 3. Angiographic Results at 4 and 9 Months
Variable In-Stent In-Segment
Minimal lumen diameter (mm)
After procedure (n  140) 2.76 0.39 2.36 0.43
At 4 months (n  30) 2.68 0.39 2.38 0.40
At 9 months (n  96) 2.51 0.48 2.21 0.45
Diameter stenosis (% of lumen diameter)
After procedure (n  140) 3.36 8.54 17.80 8.24
At 4 months (n  30) 7.18 7.86 17.74 7.57
At 9 months (n  96) 10.13 12.63 21.08 10.62
Late lumen loss (mm)
At 4 months (n  30) 0.12 0.26 0.05 0.20
At 9 months (n  96) 0.22 0.27 0.12 0.27
Late loss index*
At 4 months (n  30) 0.06 0.17 0.01 0.18
At 9 months (n  96) 0.12 0.16 0.08 0.21
Binary restenosis (%)†
At 4 months (n  30) 0.0 0.0
At 9 months (n  96) 1.0 2.1
Values are mean SD or n (number of lesions for eachmeasure). *Late loss index was defined asthe ratio of late loss to acute gain. †Binary restenosis was defined as50% diameter stenosis.
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983lute achieved high acute lesion, procedure, and device
uccess rates. Cumulative MACE rates were low and
argely driven by an unexpectedly high number of proce-
ural events unrelated to the study stent, including 1
rotocol violation (elevated cardiac enzymes at enroll-
ent), 4 sidebranch occlusion events at the time of
alloon pre-dilation, and 2 iatrogenic events related to
he IVUS 9-month follow-up. There was a low rate of
VF, no protocol-defined or ARC definite or probable
arly or late stent thromboses, and only 1 patient required
TLR through 12 months.
On the basis of the study’s QCA and IVUS results, the
esolute stent also showed promising efficacy. The primary
nd point of this trial, the in-stent late lumen loss at 9
onths, was 0.22  0.27 mm, which was significantly less
han that seen in the matched Endeavor stent cohort of the
NDEAVOR II study (18). The low level of late loss with
he Resolute stent translated into a modest level of binary
n-stent restenosis (1.0%) and binary in-segment restenosis
2.1%). Mauri et al (28) previously described the curvilinear
Table 5. Cumulative Composite of MACE at 30 Days, 6, 9, and 12 Months
Variable
30 Days
n  139 Patients
n  140 Lesions
Any MACE 4.3 (6/139)
Death 0.0 (0/139)
Cardiac-related 0.0 (0/139)
Myocardial infarction 4.3 (6/139)
Q-wave 0.0 (0/139)
Non–Q-wave 4.3 (6/139)
Target lesion revascularization (lesion level) 0.0 (0/140)
CABG 0.0 (0/140)
PTCA 0.0 (0/140)
Target vessel revascularization 0.0 (0/139)
Target vessel failure 4.3 (6/139)
Stent thrombosis
Protocol deﬁned (lesion level) 0.0 (0/140)
ARC deﬁnite/probable 0.0 (0/140)
ARC all 0.0 (0/140)
Values are %. *One patient did not complete the 12-month follow-up visit.
ARC  Academic Research Consortium; CABG  coronary artery bypass grafting; MACE  ma
Table 4. Intravascular Ultrasound Results at 4 and 9
Variable
After Proc
(n  1
EEM volume, mm3 334.58 111
Stent volume, mm3 169.21 57.4
Neointimal hyperplastic volume, mm3 N/A
Volume obstruction, % N/A
Values are mean SD (n [patients with available data for each parame
EEM external elastic membrane.revascularization of the target lesion); PTCA percutaneous transluminal coronary angioplasty.elationship between late lumen loss and angiographic
inary restenosis and predicted a restenosis rate in a popu-
ation with a mean reference vessel diameter of 2.79 mm and
mean post-procedure MLD of 2.68 mm. In our study, the
ean pre-procedure reference vessel diameter was 2.81 mm
nd the mean post-procedure MLD was 2.76 mm. Extrap-
lating from this relationship, a late lumen loss of 0.22 mm
ould correlate with approximately 1.0% to 2.0% in-stent
inary restenosis, which is indeed what we observed in this
tudy. These data support the BioLinx design hypothesis
hat extending the duration of zotarolimus release results in
ower late loss.
The 9-month IVUS results confirmed that the mean
xternal elastic membrane volume was well-preserved, indi-
ating there was no overt positive remodeling of the vessels
verall. The stent volume was also well-conserved, indicat-
ng that there was little or no recoil of the stent. In addition,
he NIH volume and percent NIH volume obstruction were
uite low, consistent with the potent antiproliferative effect
f zotarolimus. There were, however, 6 LIA noted at the
6 Months
 139 Patients
 140 Lesions
9 Months
n  139 Patients
n  140 Lesions
12 Months
n  138 Patients*
n  139 Lesions
4.3 (6/139) 7.2 (10/139) 8.7 (12/138)
0.0 (0/139) 1.4 (2/139) 2.2 (3/138)
0.0 (0/139) 0.7 (1/139) 0.7 (1/138)
4.3 (6/139) 5.8 (8/139) 5.8 (8/138)
0.0 (0/139) 0.0 (0/139) 0.0 (0/138)
4.3 (6/139) 5.8 (8/139) 5.8 (8/138)
0.0 (0/140) 0.0 (0/140) 0.7 (1/139)
0.0 (0/140) 0.0 (0/140) 0.0 (0/139)
0.0 (0/140) 0.0 (0/140) 0.7 (1/139)
0.0 (0/139) 0.0 (0/139) 0.7 (1/138)
4.3 (6/139) 6.5 (9/139) 7.2 (10/138)
0.0 (0/140) 0.0 (0/140) 0.0 (0/138)
0.0 (0/140) 0.0 (0/140) 0.0 (0/138)
0.0 (0/140) 0.7 (1/140) 0.7 (1/138)
rse cardiac events (defined as death, myocardial infarction, emergent cardiac surgery, or repeat
hs
4 Months
(n  30)
9 Months
(n  100)
) 337.46 88.12 (22) 332.50 114.28 (68)
) 167.74 44.76 (24) 169.22 57.43 (88)
3.72 4.21 (24) 6.55 7.83 (88)
2.23 2.43 (24) 3.73 4.05 (88)n
n
jor adveMont
edure
30)
.34 (94
4 (116
ter]).
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984-month IVUS follow-up. Two were edge-related, and 4
ere in the body of the stent. This is in contrast to the
ndeavor I, II, and III trials (which included IVUS follow-
p) where, in total, only 1 LIA was observed. This shows
hat the mean late loss and mean and SD of the late loss
istribution seem to shift to the left. In doing so, one would
xpect to observe some degree of negative late loss and
ositive remodeling resulting in additional LIA by IVUS.
f the 6 observed LIA in the RESOLUTE trial, only 1
equired a TLR (at 280 days). Although there have been
everal small studies that show a relationship between LIA
nd late stent thrombosis, it has not been conclusively
emonstrated (29).
onclusions
he results of the RESOLUTE feasibility study found the
esolute stent safe and effective, with high acute lesion,
rocedure, and device deployment success rates. Treatment of
atients with symptomatic ischemic heart disease and single-
essel de novo lesions by means of the Resolute stent system
esulted in sustained clinical effectiveness and very modest
hanges in vessel lumen dimensions up to 9 months and
inimal late lumen loss. This translated into very low TLR,
cceptable TVF and MACE rates, and no cases of protocol-
efined or ARC definite or probable stent thrombosis. Three
ontrolled studies (RESOLUTE US, RESOLUTE ALL
OMERS, and RESOLUTE INTERNATIONAL) are
urrently underway to confirm the RESOLUTE study’s results
n more complex lesion cohorts.
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APPENDIX
or a list of the RESOLUTE stent trial investigators, please see the online
ersion of this article.
